Reduced glutathione and glutathione disulfide in the blood of glucose-6-phosphate dehydrogenase-deficient newborns

BMC Pediatr. 2017 Jul 20;17(1):172. doi: 10.1186/s12887-017-0920-y.

Abstract

Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is commonly detected during mass screening for neonatal disease. We developed a method to measure reduced glutathione (GSH) and glutathione disulfide (GSSG) using tandem mass spectrometry (MS/MS) for detecting G6PD deficiency.

Methods: The concentration of GSH and the GSH/GSSG ratio in newborn dry-blood-spot (DBS) screening and in blood plus sodium citrate for test confirmation were examined by MS/MS using labeled glycine as an internal standard.

Results: G6PD-deficient newborns had a lower GSH content (242.9 ± 15.9 μmol/L)and GSH/GSSG ratio (14.9 ± 7.2) than neonatal controls (370.0 ± 53.2 μmol/L and 46.7 ± 19.6, respectively). Although the results showed a significance of P < 0.001 for DBS samples plus sodium citrate that were examined the first day after preparation, there were no significant differences in the mean GSH concentration and GSH/GSSG ratio between the G6PD deficiency-positive and negative groups when examined three days after sample preparation.

Conclusion: The concentration of GSH and the ratio of GSH/GSSG in blood measured using MS/MS on the first day of sample preparation are consistent with G6PD activity and are helpful for diagnosing G6PD deficiency.

Keywords: Blood; Glucose-6-phosphate dehydrogenase deficiency; Glutathione; Tandem mass spectrometry.

MeSH terms

  • Biomarkers / blood
  • Case-Control Studies
  • Dried Blood Spot Testing
  • Glucosephosphate Dehydrogenase Deficiency / blood
  • Glucosephosphate Dehydrogenase Deficiency / diagnosis*
  • Glutathione / blood*
  • Glutathione Disulfide / blood
  • Humans
  • Infant, Newborn
  • Neonatal Screening / methods*
  • Tandem Mass Spectrometry*

Substances

  • Biomarkers
  • Glutathione
  • Glutathione Disulfide